Peter Kabos MD ABRCC-2

    Clinical Researchers Showcase Series - October 2017

    Translational Medicine Research:

 View from the Trenches Newsletter


Brought to you by:

Criterium Logo Alt Tag Line w Globe Banner 2

Translational science is motivated by the need to provide effective treatments to the right patients at the right doses for a specific disease indication). The term is used mostly in the health sciences and refers to real-time translation of bench science, conducted only
in a lab, to bedside clinical practice or dissemination to population-based community interventions. (Source: NIH)

from the
Academic Breast Cancer Consortium

ABRCC Researcher Spotlight:

MEET Dr. Peter Kabos, M.D

ABRCC Director

Dr. Peter Kabos is Assistant Professor, Division of Medical Oncology at University of Colorado Cancer Center.


Dr. Kabos joined the UCD faculty in July 2009 and is a member of the breast oncology program there. He spent four years as a post-doctoral research fellow at Cedars-Sinai Medical Center studying the biology of normal and cancer stem cells in gliomas. He completed his Internal Medicine residency training at USC Keck School of Medicine in Los Angeles and a fellowship in Hematology/Oncology at the University of Colorado Denver. He received his MD from Comenius University, Slovakia.


See Publications from Dr. Kabos on


His research focus is in translating preclinical findings into novel treatments for patients with breast cancer. The Kabos Research Lab at the university focuses on hormone receptive positive breast cancer, the role of breast cancer stem cells and tumor microenvironment in treatment resistance.


See Cancer Network Case File

His specialties and certifications include: Internal Medicine, Board Certification (2006); Internal Medicine - Medical Oncology, Board Certification (2009). His awards and honors include the ASCO Young Investigator Award and NIH/NCI K08 Career Development Award.


About University of Colorado Cancer Center
The University of Colorado Cancer Center is the Rocky Mountain region's only National Cancer Institute-designated comprehensive cancer center. NCI has given only 40 cancer centers this designation, deeming membership as "the best of the best."
Learn more at:  UC Denver School of Medicine


for Translational Research

The important conceptual difference between the two predominant research group approaches used today (a Clinical Trials Group vs. Consortia) is seen in this consortia model.  With its highly experienced clinical scientists, ABRCC becomes involved on an intellectual advisory level with every step of clinical investigation in a breast cancer study. Classical clinical trials groups "just run the study" with the main substantive role being patient accrual.


To read more on ABRCC and the details of why the consortia model creates fast results, please visit our website.

The Oncology Consortia of Criterium

The Oncology Consortia of Criterium Global CRO are a collaboration of outstanding Cancer Research Consortia that deliver innovative research and unparalleled expertise:

  • AGICC:  Academic GI Cancer Consortium
  • AMyC:  Academic Myeloma Consortium
  • ATOMIC:  Academic Thoracic Oncology Medical Investigators Consortium
  • ABRCC:  Academic Breast Cancer Consortium

ABRCC Cube FULL Logo 2

Read more about Criterium Inc Global CRO

and The Oncology Consortia of Criterium on our website